Events | 2017.03.16
Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
ZUG, Switzerland, March 16, 2017 /PRNewswire/ -- CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the European Commission (EC) has approved a label extension...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]tients-with-hae-616299374.html
